1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PharmaPoint: Macular Edema and Macular Degeneration - Current and Future Players

PharmaPoint: Macular Edema and Macular Degeneration - Current and Future Players

Summary

GlobalData has released its pharma report, “PharmaPoint: Macular Edema and Macular Degeneration - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Macular Edema and Macular Degeneration. The report identifies and analyses the key companies shaping and driving the global Macular Edema and Macular Degeneration market. The report provides insight into the competitive Macular Edema and Macular Degeneration landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Scope

- Investigation of current and future market competition for Macular Edema and Macular Degeneration
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Macular Edema and Macular Degeneration sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving Macular Edema and Macular Degeneration market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Macular Edema and Macular Degeneration market landscape? Identify, understand and capitalize

Table Of Contents

PharmaPoint: Macular Edema and Macular Degeneration - Current and Future Players
1 Table of Contents
2 Introduction 12
2.1 Related Reports 13
3 Market Outlook 15
3.1 Global Markets 15
3.1.1 Forecast 15
3.1.2 Drivers and Barriers - Global Issues 23
4 Current and Future Players 27
4.1 Overview 27
4.2 Trends in Corporate Strategy 29
4.3 Company Profiles 30
4.3.1 Roche/Genentech 30
4.3.2 Novartis 34
4.3.3 Regeneron 37
4.3.4 Bayer 41
4.3.5 Valeant 45
4.3.6 Allergan 48
4.3.7 Alimera Sciences 51
4.3.8 Ampio Pharmaceuticals 55
4.3.9 Ophthotech 57
4.3.10 Acucela 61
4.3.11 Ohr Pharmaceuticals 65
5 Appendix 68
5.1 Bibliography 68
5.2 Abbreviations 74
5.3 Methodology 77
5.4 Forecasting Methodology 77
5.4.1 Diagnosed ME and AMD Patients 77
5.4.2 Percentage of Drug-Treated Patients 78
5.4.3 General Pricing Assumptions 78
5.5 Primary Research - KOLs Interviewed for this Report 80
5.6 Primary Research - High-Prescribers Survey 81
5.7 About the Authors 82
5.7.1 Analyst 82
5.7.2 Therapy Area Director 82
5.7.3 Global Head of Healthcare 83
5.8 About GlobalData 84
5.9 Disclaimer 84

1.1 List of Tables

Table 1: Global Sales Forecast ($m) for ME, 2013-2023 17
Table 2: Global Sales Forecast ($m) for AMD, 2013-2023 20
Table 3: ME and AMD Markets - Drivers and Barriers, 2013-2023 23
Table 4: Key Companies in the ME and AMD Markets in the 7MM, 2014 27
Table 5: Roche/Genentech's ME and AMD Portfolio Assessment, 2014 33
Table 6: Novartis' ME and AMD Portfolio Assessment, 2014 36
Table 7: Regeneron's ME and AMD Portfolio Assessment, 2014 40
Table 8: Bayer's ME and AMD Portfolio Assessment, 2014 44
Table 9: Valeant's AMD Portfolio Assessment, 2014 47
Table 10: Allergan's ME and AMD Portfolio Assessment, 2014 50
Table 11: Alimera Sciences' ME Portfolio Assessment, 2014 53
Table 12: Ampio's ME Portfolio Assessment, 2014 56
Table 13: Ophthotech's AMD Portfolio Assessment, 2014 60
Table 14: Acucela's AMD Portfolio Assessment, 2014 64
Table 15: Ohr Pharmaceutical's AMD Portfolio Assessment, 2014 67
Table 16: Surveyed High-Prescribing Physicians (Non-KOLs), by Country 81

1.2 List of Figures

Figure 1: Global Sales for ME by Region, 2013-2023 18
Figure 2: Individual Drug Sales for ME 2013-2023 19
Figure 3: Global Sales for AMD by Region, 2013-2023 21
Figure 4: Individual Drug Sales for AMD 2013-2023 22
Figure 5: Global Sales of Branded Products for ME and AMD by Company, 2013-2023 28
Figure 6: Company Portfolio Gap Analysis in ME and AMD, 2013-2023 29
Figure 7: Roche/Genentech's SWOT Analysis in ME and AMD, 2013-2023 33
Figure 8: Novartis' SWOT Analysis in ME and AMD, 2013-2023 37
Figure 9: Regeneron's SWOT Analysis in ME and AMD, 2013-2023 41
Figure 10: Bayer's SWOT Analysis in ME and AMD, 2013-2023 44
Figure 11: Valeant's SWOT Analysis in AMD, 2013-2023 47
Figure 12: Allergan's SWOT Analysis in ME and AMD, 2013-2023 51
Figure 13: Alimera Sciences' SWOT Analysis in ME, 2013-2023 54
Figure 14: Ampio's SWOT Analysis in ME, 2013-2023 57
Figure 15: Ophthotech's SWOT Analysis in AMD, 2013-2023 61
Figure 16: Acucela's SWOT Analysis in AMD, 2013-2023 64
Figure 17: Ohr Pharmaceutical's SWOT Analysis in AMD, 2013-2023 67

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.